Results

1–10 of 14 results for model

Inhibition of C1q Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy
Patrick Dewey Williams, MD
Annual Meeting Talks
2022
Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022
Modeling Zone as a Proxy for Absolute Avascular Retina Area and Retinopathy of Prematurity Risk
Darius M. Moshfeghi, MD, FASRS
Annual Meeting Talks
2022
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Rho-kinase Inhibition on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy
Leo A. Kim, MD, PhD
Annual Meeting Talks
2021
Modeling the Effect of Longer-Acting Drugs and Reimbursement Changes
Robert A Diamond, BBA
Updates from the Field
2022
Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020
Predictive Modeling of Proliferative Diabetic Retinopathy and DME Based on Analysis of High-Value Biomarkers
Kameran Lashkari, MD, FASRS
On Demand Cases, Courses, and Papers
2019
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
Episode 208: Dr. Chrisfouad Alabiad on Medical Education, Flipped Classroom Teaching Model, and Ophthalmology Residency Applications
Jayanth Sridhar, MD
Member Podcasts
2020